AIRTIVITY
A Phase III, randomized, double-blind, placebo-controlled study to assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with Bronchiectasis (The AIRTIVITY® Study).
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Bronchiectasis
Study Purpose
A placebo-controlled study to assess the Efficacy, Safety, and Tolerability for BI 1291583 2.5mg administered once daily for up to 76 weeks in patients with Bronchiectasis.
Who Can Participate
Clinical history consistent with bronchiectasis, daily sputum producers, history of documented pulmonary exacerbations requiring antibotics
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Ahuja Medical Center
3999 Richmond Rd
Beachwood OH, 44122
- UH IRB: SITE00002494
- StudyID: 2025-01678
- ClinicalTrials.gov: NCT06872892
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422